

## Summary statistics - quantitative results

(Groups: measurement principle, manufacturer of kit)

Filter: Czech Republic, minimal size of the groups n = 5

## EQA round: E22/21 - Hormones 2

Deadline: 04.05.2021

RoM = robust average	AV = assigned value	Dmax = acceptable percent difference
SD = standard deviation	CRV = certified reference value	LL = lower limit
CV = coefficient of variation	RV = reference value	UL = upper limit
Ntot = total number of the participants	CVE = consensus value from experts	Neva = number of evaluated participants
Nout = number of results excluded before calculation	CVP = consensus value from all participants	Nsuc = number of successful participants
	CVPG = consensus value from participants groups	Srel = success (relative)
	U <sub>AV</sub> = expanded uncertainty of the assigned value (k = 2)	

Test	[unit]						Comparability							
		RoM	SD	CV [%]	N <sub>tot</sub>	N <sub>out</sub>	AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL	N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub>
<b>(193) Ferritin</b>					120							114	112	98%
— Samples and groups	[µg/L]													
<b>Sample A</b>		158	25	16	120							114	114	100%
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott		172	13	7,2	40	0	CVPG	171	3,3	24%	129	213	40	
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter		112	12	11	11	0	CVPG	117	3,3	24%	88,9	146	11	
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		174	9,1	5,2	22	0	CVPG	176	1,6	24%	133	219	22	
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (162) Siemens (Atellica)		141	7,1	5,0	10	0	CVPG	140	2,8	24%	106	174	10	
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (179) Siemens		139	8,7	6,3	10	0	CVPG	139	3,9	24%	105	173	10	
(6) IMT, IMN; (58) Beckman Coulter (AU)		137	3,0	2,2	5	0	CVPG	148	4,8	24%	112	184	5	
(6) IMT, IMN; (60) Roche		166	12	7,3	14	0	CVPG	174	2,9	24%	132	216	14	
Other					8	0							2	
								1x 3/25, 1x 4/29, 1x 4/40, 1x 4/149, 2x 6/1, 1x 6/5, 1x 6/46						
<b>Sample B</b>		128	23	18	120							114	112	98%
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott		139	13	9,2	40	0	CVPG	138	3,6	24%	104	172	40	
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter		85,4	7,3	8,6	11	0	CVPG	90,4	3,2	24%	68,7	113	11	
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		143	14	10	22	0	CVPG	142	2,0	24%	107	177	22	
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (162) Siemens (Atellica)		110	16	15	10	0	CVPG	110	5,1	24%	83,6	137	10	
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (179) Siemens		111	13	12	10	0	CVPG	110	4,1	24%	83,6	137	10	
(6) IMT, IMN; (58) Beckman Coulter (AU)		122	11	9,4	5	0	CVPG	126	5,0	24%	95,7	157	5	
(6) IMT, IMN; (60) Roche		141	15	10	14	0	CVPG	145	3,4	24%	110	180	14	
Other					8	0							2	
								1x 3/25, 1x 4/29, 1x 4/40, 1x 4/149, 2x 6/1, 1x 6/5, 1x 6/46						
<b>(320) LH</b>					96							95	94	99%
— Samples and groups	[U/L]													
<b>Sample A</b>		9,76	1,9	20	96							95	94	99%
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott		8,38	0,46	5,5	31	0	CVPG	8,31	0,11	15%	7,06	9,56	31	
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter		7,90	0,38	4,8	10	0	CVPG	7,92	0,14	15%	6,73	9,11	10	
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		11,7	0,45	3,8	28	0	CVPG	11,6	0,063	15%	9,86	13,4	28	
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (162) Siemens (Atellica)		9,30	0,15	1,6	9	0	CVPG	9,54	0,20	15%	8,1	11	9	
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (179) Siemens		9,05	0,52	5,7	7	0	CVPG	9,06	0,18	15%	7,7	10,5	7	
Other					11	0							10	
								4x 3/25, 4x 4/29, 1x 4/40, 1x 4/149, 1x 4/164						
<b>Sample B</b>		30,2	5,1	17	96							95	94	99%
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott		26,0	1,4	5,2	31	0	CVPG	26	0,33	15%	22,1	29,9	31	
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter		24,4	1,1	4,5	10	0	CVPG	24	0,39	15%	20,4	27,6	10	
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		34,0	1,4	4,1	28	0	CVPG	33,8	0,17	15%	28,7	38,9	28	
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (162) Siemens (Atellica)		32,4	0,96	2,9	9	0	CVPG	33,6	0,80	15%	28,5	38,7	9	
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (179) Siemens		32,8	3,2	9,7	7	0	CVPG	32,8	0,73	15%	27,8	37,8	7	
Other					11	0							10	
								4x 3/25, 4x 4/29, 1x 4/40, 1x 4/149, 1x 4/164						
<b>(321) FSH</b>					99							98	97	99%
— Samples and groups	[U/L]													
<b>Sample A</b>		5,69	0,61	11	99							98	98	100%
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott		5,31	0,30	5,6	32	0	CVPG	5,26	0,065	15%	4,47	6,05	32	
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter		5,94	0,33	5,6	12	0	CVPG	5,92	0,10	15%	5,03	6,81	12	
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		5,46	0,26	4,8	27	0	CVPG	5,45	0,035	15%	4,63	6,27	27	
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (162) Siemens (Atellica)		6,75	0,22	3,3	9	0	CVPG	6,7	0,14	15%	5,69	7,71	9	
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (179) Siemens		6,64	0,64	9,7	8	0	CVPG	6,5	0,13	15%	5,52	7,48	8	
Other					11	0							10	
								4x 3/25, 4x 4/29, 1x 4/40, 1x 4/149, 1x 4/164						
<b>Sample B</b>		8,89	0,97	11	99							98	97	99%

## Summary statistics - quantitative results

(Groups: measurement principle, manufacturer of kit)

Filter: Czech Republic, minimal size of the groups n = 5

## EQA round: E22/21 - Hormones 2

Deadline: 04.05.2021

Test	[unit]						Comparability							N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub>
		RoM	SD	CV [%]	N <sub>tot</sub>	N <sub>out</sub>	AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL					
<b>(321) FSH</b>	[U/L]				99									98	97	99%
Samples and groups																
<b>Sample B</b>		8,89	0,97	11	99									98	97	99%
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott		8,35	0,39	4,7	32	0	CVPG	8,33	0,11	15%	7,08	9,58		32		
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter		8,81	0,59	6,7	12	0	CVPG	8,99	0,13	15%	7,64	10,4		12		
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		8,59	0,43	5,0	27	0	CVPG	8,63	0,056	15%	7,33	9,93		27		
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (162) Siemens (Atellica)		10,9	0,52	4,8	9	0	CVPG	10,7	0,19	15%	9,09	12,4		9		
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (179) Siemens		10,5	0,72	6,9	8	0	CVPG	10,7	0,17	15%	9,09	12,4		8		
Other					11	0		4x 3/25, 4x 4/29, 1x 4/40, 1x 4/149, 1x 4/164						10		
<b>(322) Prolactin</b>	[mU/L]				106									104	102	98%
Samples and groups																
<b>Sample A</b>		328	42	13	106									104	103	99%
(3) FIA (FEIA, TRACE); (25) TOSOH		286	11	3,7	5	0	CVPG	290	16	16%	243	337		5		
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott		341	16	4,7	34	0	CVPG	339	3,9	16%	284	394		34		
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter		299	11	3,6	12	0	CVPG	299	5,2	16%	251	347		12		
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (29) Siemens (Immulin)		294	5,2	1,8	5	0	CVPG	298	5,4	16%	250	346		5		
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		365	14	3,9	31	0	CVPG	357	2,0	16%	299	415		31		
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (162) Siemens (Atellica)		270	11	4,2	9	0	CVPG	266	5,1	16%	223	309		9		
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (179) Siemens		274	16	5,9	7	0	CVPG	267	5,2	16%	224	310		7		
Other					3	0		1x 4/40, 1x 4/149, 1x 4/164						1		
<b>Sample B</b>		168	26	16	106									104	102	98%
(3) FIA (FEIA, TRACE); (25) TOSOH		147	5,6	3,8	5	0	CVPG	147	5,4	16%	123	171		5		
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott		168	9,1	5,4	34	0	CVPG	168	2,1	16%	141	195		34		
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter		151	9,5	6,3	12	0	CVPG	154	2,5	16%	129	179		12		
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (29) Siemens (Immulin)		139	2,2	1,6	5	0	CVPG	140	2,3	16%	117	163		5		
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		197	7,3	3,7	31	0	CVPG	192	1,1	16%	161	223		31		
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (162) Siemens (Atellica)		138	2,1	1,6	9	0	CVPG	139	2,1	16%	116	162		9		
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (179) Siemens		139	8,2	5,9	7	0	CVPG	138	2,0	16%	115	161		7		
Other					3	0		1x 4/40, 1x 4/149, 1x 4/164						1		
<b>(325) Insulin</b>	[mU/L]				29									27	27	100%
Samples and groups																
<b>Sample A</b>		41,2	7,2	17	29									27	27	100%
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott		32,2	1,3	4,1	7	0	CVPG	32	0,56	20%	25,6	38,4		7		
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		48,3	1,5	3,1	9	0	CVPG	46,5	0,49	20%	37,2	55,8		9		
Other					13	0		1x 1/36, 1x 3/25, 3x 4/12, 4x 4/162, 4x 4/179						11		
<b>Sample B</b>		78,1	13	16	29									27	27	100%
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott		62,4	3,0	4,9	7	0	CVPG	60,8	0,82	20%	48,6	73		7		
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		90,8	2,9	3,2	9	0	CVPG	86,9	0,96	20%	69,5	105		9		
Other					13	0		1x 1/36, 1x 3/25, 3x 4/12, 4x 4/162, 4x 4/179						11		
<b>(326) Folate</b>	[nmol/L]				125									123	111	90%
Samples and groups																
<b>Sample A</b>		9,62	2,1	22	125									123	116	94%
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott		11,2	1,0	9,0	45	0	CVPG	11,4	0,25	27%	8,32	14,5		45		
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter		11,0	0,54	4,9	12	0	CVPG	10,8	0,24	27%	7,88	13,8		12		
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		7,63	1,2	16	44	0	CVPG	7,43	0,13	27%	5,42	9,44		44		
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (162) Siemens (Atellica)		10,2	0,44	4,4	9	0	CVPG	10,5	0,61	27%	7,66	13,4		9		
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (179) Siemens		9,34	1,3	14	11	0	CVPG	9,51	0,32	27%	6,94	12,1		11		
Other					4	0		1x 3/25, 1x 4/29, 1x 4/40, 1x 4/149						2		
<b>Sample B</b>		9,59	2,2	23	125									123	113	92%
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott		11,1	1,4	12	45	0	CVPG	11,2	0,29	27%	8,17	14,3		45		

## Summary statistics - quantitative results

(Groups: measurement principle, manufacturer of kit)

Filter: Czech Republic, minimal size of the groups n = 5

## EQA round: E22/21 - Hormones 2

Deadline: 04.05.2021

Test	[unit]						Comparability							N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub>
		RoM	SD	CV [%]	N <sub>tot</sub>	N <sub>out</sub>	AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL					
<b>(326) Folate</b>	[nmol/L]				125									123	111	90%
Samples and groups																
<b>Sample B</b>		9,59	2,2	23	125									123	113	92%
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter		11,5	0,45	3,9	12	0	CVPG	11,2	0,24	27%	8,17	14,3		12		
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		7,56	0,98	13	44	0	CVPG	7,48	0,13	27%	5,46	9,5		44		
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (162) Siemens (Atellica)		9,65	0,22	2,3	9	0	CVPG	9,97	0,51	27%	7,27	12,7		9		
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (179) Siemens		9,02	1,5	17	11	0	CVPG	8,96	0,37	27%	6,54	11,4		11		
Other					4	0								2		
		1x 3/25, 1x 4/29, 1x 4/40, 1x 4/149														
<b>(327) Vitamin B12</b>	[pmol/L]				105									103	101	98%
Samples and groups																
<b>Sample A</b>		248	38	15	105									103	102	99%
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott		236	23	9,7	35	0	CVPG	243	4,8	20%	194	292		35		
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter		181	14	8,0	14	0	CVPG	182	4,4	20%	145	219		14		
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		275	13	4,7	37	0	CVPG	273	2,2	20%	218	328		37		
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (162) Siemens (Atellica)		285	54	19	8	0	CVPG	278	12	20%	222	334		8		
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (179) Siemens		249	24	9,8	7	0	CVPG	254	8,4	20%	203	305		7		
Other					4	0								2		
		1x 3/25, 1x 4/29, 1x 4/40, 1x 4/149														
<b>Sample B</b>		666	71	11	105									103	102	99%
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott		654	54	8,3	35	0	CVPG	656	10	20%	524	788		35		
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter		551	32	5,9	14	0	CVPG	543	9,2	20%	434	652		14		
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		691	25	3,6	37	0	CVPG	688	3,9	20%	550	826		37		
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (162) Siemens (Atellica)		747	100	14	8	0	CVPG	750	23	20%	600	900		8		
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (179) Siemens		727	20	2,8	7	0	CVPG	732	20	20%	585	879		7		
Other					4	0								2		
		1x 3/25, 1x 4/29, 1x 4/40, 1x 4/149														
<b>(319) Vitamin B12 (active)</b>	[pmol/L]				31									0		
Samples and groups																
<b>Sample A</b>		69,7	7,7	11	31									26	25	96%
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott		68,9	9,0	13	20	0	CVPG	68,5	4,5	20%	54,8	82,2		20		
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		70,2	3,7	5,3	6	0	CVPG	68,7	4,6	20%	54,9	82,5		6		
Other					5	0								0		
		2x 4/162, 3x 4/179														
<b>Sample B</b>		235	120	51	31									0		
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott		207	98	48	20	0	CVPG	211	50	20%	168	254		0		
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		271	180	66	6	0	CVPG	271	140	20%	216	326		0		
Other					5	0								0		
		2x 4/162, 3x 4/179														
<b>(328) hGH</b>	[mU/L]				22									20	18	90%
Samples and groups																
<b>Sample A</b>		14,3	1,6	11	22									20	18	90%
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (29) Siemens (Immulin)		14,6	1,3	9,1	8	0	CVPG	15,2	0,27	19%	12,3	18,1		8		
Other					14	0								12		
		1x 1/36, 1x 3/25, 3x 4/12, 4x 4/60, 2x 4/164, 2x 4/183, 1x 4/999														
<b>Sample B</b>		40,4	3,5	8,7	22									20	18	90%
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (29) Siemens (Immulin)		40,2	2,2	5,5	8	0	CVPG	40,4	0,55	19%	32,7	48,1		8		
Other					14	0								12		
		1x 1/36, 1x 3/25, 3x 4/12, 4x 4/60, 2x 4/164, 2x 4/183, 1x 4/999														
<b>(329) IGF-1</b>	[µg/L]				25									24	23	96%
Samples and groups																
<b>Sample A</b>		533	250	46	25									24	23	96%
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (29) Siemens (Immulin)		878	99	11	7	0	CVPG	832	18	22%	648	1020		7		
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		354	28	7,9	7	0	CVPG	368	14	22%	287	449		7		
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (164) DiaSorin		488	60	12	7	0	CVPG	515	25	22%	401	629		7		
Other					4	0								3		
		3x 4/183, 1x 4/999														
<b>Sample B</b>		487	210	42	25									24	23	96%
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (29) Siemens (Immulin)		775	88	11	7	0	CVPG	736	13	22%	574	898		7		

## Summary statistics - quantitative results

(Groups: measurement principle, manufacturer of kit)

Filter: Czech Republic, minimal size of the groups n = 5

## EQA round: E22/21 - Hormones 2

Deadline: 04.05.2021

Test	[unit]						Comparability							N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub>
		RoM	SD	CV [%]	N <sub>tot</sub>	N <sub>out</sub>	AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL					
<b>(329) IGF-1</b>					25									24	23	96%
— Samples and groups	[µg/L]															
<b>Sample B</b>		487	210	42	25									24	23	96%
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		331	19	5,7	7	0	CVPG	342	14	22%	266	418		7		
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (164) DiaSorin		478	56	12	7	0	CVPG	484	22	22%	377	591		7		
Other					4	0								3		
								3x 4/183, 1x 4/999								
<b>(390) Renin</b>					18									18	17	94%
— Samples and groups	[ng/L]															
<b>Sample A</b>		38,5	7,0	18	18									18	17	94%
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (164) DiaSorin		35,1	4,3	12	8	0	CVPG	34,9	0,62	20%	27,9	41,9		8		
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (183) Immunodiagnostic Systems		46,0	0,380,82		6	0	CVPG	46,3	0,90	20%	37	55,6		6		
Other					4	0								4		
								3x 1/36, 1x 2/66								
<b>Sample B</b>		43,0	7,5	17	18									18	17	94%
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (164) DiaSorin		39,0	6,1	16	8	0	CVPG	39,9	0,62	20%	31,9	47,9		8		
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (183) Immunodiagnostic Systems		50,6	3,4	6,8	6	0	CVPG	50,6	0,94	20%	40,4	60,8		6		
Other					4	0								4		
								3x 1/36, 1x 2/66								
<b>(392) IGF-BP3</b>					8									6	5	83%
— Samples and groups	[µg/L]															
<b>Sample A</b>		3640	700	19	8									6	5	83%
Other					8	0								6		
								1x 1/36, 1x 1/66, 4x 4/29, 1x 4/60, 1x 4/183								
<b>Sample B</b>		3510	550	16	8									6	5	83%
Other					8	0								6		
								1x 1/36, 1x 1/66, 4x 4/29, 1x 4/60, 1x 4/183								
<b>(393) C-peptide</b>					108									106	103	97%
— Samples and groups	[pmol/L]															
<b>Sample A</b>		252	61	24	108									106	104	98%
(3) FIA (FEIA, TRACE); (25) TOSOH		201	18	8,8	5	0	CVPG	201	50	20%	160	242		5		
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott		239	13	5,3	31	0	CVPG	239	5,4	20%	191	287		31		
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter		156	5,9	3,8	5	0	CVPG	156	17	20%	124	188		5		
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (29) Siemens (Immulin)		205	19	9,4	12	0	CVPG	205	14	20%	164	246		12		
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		317	10	3,3	37	0	CVPG	317	3,8	20%	253	381		37		
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (162) Siemens (Atellica)		201	8,7	4,3	9	0	CVPG	201	11	20%	160	242		9		
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (179) Siemens		193	19	9,6	7	0	CVPG	197	14	20%	157	237		7		
Other					2	0								0		
								1x 1/36, 1x 4/164								
<b>Sample B</b>		377	82	22	108									106	103	97%
(3) FIA (FEIA, TRACE); (25) TOSOH		323	18	5,7	5	0	CVPG	323	52	20%	258	388		5		
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott		361	21	5,7	31	0	CVPG	359	8,6	20%	287	431		31		
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter		232	25	11	5	0	CVPG	232	71	20%	185	279		5		
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (29) Siemens (Immulin)		321	17	5,4	12	0	CVPG	321	12	20%	256	386		12		
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		464	16	3,5	37	0	CVPG	464	5,9	20%	371	557		37		
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (162) Siemens (Atellica)		302	6,4	2,1	9	0	CVPG	302	7,9	20%	241	363		9		
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (179) Siemens		297	40	13	7	0	CVPG	309	27	20%	247	371		7		
Other					2	0								0		
								1x 1/36, 1x 4/164								
<b>(394) SHBG</b>					57									55	53	96%
— Samples and groups	[nmol/L]															
<b>Sample A</b>		29,8	1,8	6,1	57									55	55	100%
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott		29,7	1,9	6,5	18	0	CVPG	29,9	0,55	20%	23,9	35,9		18		
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter		30,1	1,4	4,7	5	0	CVPG	30,6	0,84	20%	24,4	36,8		5		
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		30,1	1,2	3,9	19	0	CVPG	29,7	0,23	20%	23,7	35,7		19		
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (179) Siemens		28,5	1,1	3,9	6	0	CVPG	29,7	0,80	20%	23,7	35,7		6		
Other					9	0								7		
								1x 1/36, 4x 4/29, 3x 4/162, 1x 4/999								
<b>Sample B</b>		33,4	2,2	6,7	57									55	53	96%

## Summary statistics - quantitative results

(Groups: measurement principle, manufacturer of kit)

Filter: Czech Republic, minimal size of the groups n = 5

## EQA round: E22/21 - Hormones 2

Deadline: 04.05.2021

Test	[unit]							Comparability								
		RoM	SD	CV [%]	N <sub>tot</sub>	N <sub>out</sub>	AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL	N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub>		
<b>(394) SHBG</b>	[nmol/L]													55	53	96%
Samples and groups																
<b>Sample B</b>		33,4	2,2	6,7	57							55	53	96%		
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott		33,3	2,8	8,3	18	0	CVPG	33,7	0,70	20%	26,9	40,5	18			
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter		34,4	1,0	3,0	5	0	CVPG	34,2	0,92	20%	27,3	41,1	5			
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		33,6	1,5	4,4	19	0	CVPG	33,2	0,25	20%	26,5	39,9	19			
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (179) Siemens		32,8	1,9	5,8	6	0	CVPG	33,5	0,89	20%	26,8	40,2	6			
Other					9	0							7			
1x 1/36, 4x 4/29, 3x 4/162, 1x 4/999																
<b>(405) Parathyroid hormone (PTH)</b>	[pmol/L]													52	45	87%
Samples and groups																
<b>Sample A</b>		25,1	5,1	20	54							52	51	98%		
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott		31,8	2,2	7,1	12	0	CVPG	31,6	0,80	23%	24,3	38,9	12			
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter		24,5	0,58	2,4	10	0	CVPG	24,9	0,87	23%	19,1	30,7	10			
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		20,9	0,96	4,6	20	0	CVPG	20,7	0,33	23%	15,9	25,5	20			
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (162) Siemens (Atellica)		25,7	1,1	4,1	5	0	CVPG	25,9	0,82	23%	19,9	31,9	5			
Other					7	0							5			
1x 3/25, 1x 4/29, 4x 4/179, 1x 4/999																
<b>Sample B</b>		0,862	0,33	39	54							52	46	88%		
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (1) Abbott		1,35	0,16	12	12	0	CVPG	1,37	0,041	23%	1,05	1,69	12			
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (12) Beckman Coulter		0,760	0,055	7,2	10	0	CVPG	0,796	0,031 ± 0,284	0,52	1,08	10				
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		0,707	0,24	35	20	0	CVPG	0,661	0,029 ± 0,276	0,385	0,937	20				
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (162) Siemens (Atellica)		0,700	0,000	0,00	5	0	CVPG	0,655	0,048 ± 0,276	0,379	0,931	5				
Other					7	0							5			
1x 3/25, 1x 4/29, 4x 4/179, 1x 4/999																
<b>(407) Parathyroid hormone (PTH 1-84)</b>	[pmol/L]													26	22	85%
Samples and groups																
<b>Sample A</b>		18,2	1,8	9,8	27							26	26	100%		
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		18,8	0,99	5,2	22	0	CVPG	19,4	0,18	17%	16,1	22,7	22			
Other					5	0							4			
4x 4/164, 1x 4/183																
<b>Sample B</b>		0,930	0,22	23	27							26	22	85%		
(4) LIA (CLIA, CMIA, ECLIA, LOCI); (60) Roche		0,995	0,15	16	22	0	CVPG	1,03	0,020 ± 0,21	0,826	1,24	22				
Other					5	0							4			
4x 4/164, 1x 4/183																

st\_kn\_p

End of report

Printed: 19.05.2021